The DIS3L2 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the gene encoding DIS3L2, a 3′-5′ exoribonuclease crucial for RNA decay, has been subject to genomic disruption. This loss-of-function model is generated in the A-549 human lung carcinoma epithelial cell line, providing a robust platform for investigating DIS3L2-dependent regulatory mechanisms in a cancer-relevant background.
The host A-549 cell line, originally isolated from a 58-year-old male with lung carcinoma, serves as a widely used model for human alveolar basal epithelial cells. These cells retain key characteristics of type II pulmonary epithelial cells, making them a valuable tool for dissecting mechanisms of lung cancer, drug metabolism, and cellular responses to toxic insults.
DIS3L2 functions as a critical 3′-5′ exoribonuclease that selectively degrades uridylated RNA substrates, including pre-let-7 microRNAs and specific mRNAs. Its activity is tightly coupled to the LIN28A-TUT4/TUT7 uridylation axis: LIN28A recruits TUT4 (ZCCHC11) and TUT7 (ZCCHC6) to add oligo-uridine tails, thereby marking RNAs for DIS3L2-mediated decay. Consequently, DIS3L2 acts downstream of LIN28A, TUT4, and TUT7 to post-transcriptionally control gene expression. Loss of DIS3L2 disrupts this RNA surveillance pathway, leading to accumulation of oncogenic pre-let-7 miRNAs and other uridylated mRNAs, which can drive tumorigenic processes.
In A-549 lung adenocarcinoma cells, DIS3L2 inactivation is particularly relevant for studying the interplay between RNA decay defects and oncogenesis. This polyclonal knockout population enables investigation of how dysregulated uridylation-mediated RNA turnover contributes to uncontrolled proliferation, altered epithelial differentiation, and therapeutic resistance. As DIS3L2 mutations and loss of function are associated with Wilms tumor and overgrowth syndromes, this model also facilitates cross-cancer comparisons of RNA surveillance mechanisms.
This knockout tool is ideally suited for RNA stability assays using actinomycin D chase protocols, genome-wide transcriptome profiling via RNA-seq, and targeted quantification of let-7 miRNA levels by RT-qPCR. Additionally, researchers can employ immunoblotting to confirm DIS3L2 protein loss, perform cell proliferation and colony formation assays to assess oncogenic phenotypes, and use RNA immunoprecipitation to map DIS3L2-RNA interactions. These applications support studies in cancer biology, tumor suppressor mechanisms, and RNA decay, as well as drug discovery efforts aimed at modulating RNA surveillance pathways. For additional technical information, please contact Ascent Research.
